From MarketBeat:

Czech National Bank increased its stake in Regeneron Pharmaceuticals by 46.1% during the third quarter, now owning 18,657 shares valued at $15,354,000. Other hedge funds, such as Ronald Blue Trust, Rehmann Capital Advisory Group, Cassia Capital Partners, Equitable Holdings, and Diversified Trust Co, also increased their holdings in the biopharmaceutical company. Several research firms have commented on REGN, including Argus, Bank of America, and TD Cowen, all of which boosted their target prices. Director Arthur F. Ryan and SVP Christopher R. Fenimore sold shares of the company’s stock. Insider transactions have totaled 4,918 shares in the last three months and 8.83% of the stock is owned by insiders. REGN stock is currently trading at $873.97. The company reported 14.5% growth in revenue in the last quarter, exceeding analysts’ expectations.

Overall, institutional investors have been increasing their holdings in Regeneron Pharmaceuticals, while insider selling has also been evident in the past three months. Stock prices have increased, as the company’s revenue has shown growth. Hedge funds and other institutional investors currently own over 80% of the company’s stock. Analysts have given REGN a “Moderate Buy” rating. The company’s stock peaked at $873.97 during trading hours on Wednesday. Analysts expect Regeneron Pharmaceuticals, Inc. to post 36.08 earnings per share for the current year. MarketBeat is closely monitoring these developments on an ongoing basis.



Read more: Czech National Bank Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)